Inactive Instrument

Highlights Active Biotech AB Xetra

Equities

BTPC

SE0001137985

End-of-day quote Xetra Other stock markets
- ^EUR	-

05-22	Active Biotech Secures Exclusive Licensing Rights to Multiple Myeloma Drug	MT
05-22	Active Biotech Enters into an Exclusive License Agreement with the Wistar Institute of Anatomy and Biology	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Active Biotech Secures Exclusive Licensing Rights to Multiple Myeloma Drug	05-22	MT
Active Biotech Enters into an Exclusive License Agreement with the Wistar Institute of Anatomy and Biology	05-22	CI
Active Biotech AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops	04-03	CI
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-08	CI
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-08	CI
Active Biotech AB Provides Update on the Scheduled Clinical Program for 2024	12-22	CI
Active Biotech Teams Up with US Research Group on Clinical Study of Laquinimod Eye Drops	12-06	MT
Rights Issue: 3 new shares @ 0.45 SEK for 7 existing shares	11-14	FA
Active Biotech AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Active Biotech AB Announces Two Abstracts with Preclinical Data for Tasquinimod in Myelofibrosis and Myelodysplastic Syndrome Have Been Accepted for Presentation At Ash 2023	11-02	CI
Active Biotech AB Announces Successful Completion of Dose Escalation of Tasquinimod	11/09/23	CI
Active Biotech AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23	CI
Active Biotech Signs Collaboration Deal For Blood Cancer Drug Clinical Trial	31/07/23	MT
Active Biotech AB Enters into Clinical Trial Collaboration Agreement for a Clinical Study with Tasquinimod in Myelofibrosis	31/07/23	CI
Active Biotech Announces Positive Interim Data from an Ongoing Study with Tasquinimod in Relapsed and Refractory Multiple Myeloma	26/05/23	CI
Active Biotech AB Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23	CI
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	09/02/23	CI
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2022	09/02/23	CI
Active Biotech AB Confirms Positive Clinical Safety Profile of Laquinimod Eye Drops	30/01/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Active Biotech AB Xetra

Equities

BTPC

SE0001137985

Highlights

Filters